Current status and guidelines for the assessment of tumour vascular support with dynamic contrast-enhanced computed tomography
Creators
- 1. University of Sussex, Clinical Imaging Sciences Centre, Brighton and Sussex Medical School, Falmer (United Kingdom)
- 2. Robarts Research Institute, Imaging Research Laboratories, London, Ontario (Canada)
- 3. St Thomas' Hospital, Division of Imaging Sciences and Biomedical Engineering, King's College London, London (United Kingdom)
- 4. Computed Tomography H IM CT PLM-E PA, Siemens Healthcare Sector, Forchheim (Germany)
- 5. INSERM U970 PARCC, Hopital Europeen Georges Pompidou (HEGP), Paris (France)
- 6. Eberhard Karls University, Department of Neuroradiology, Tuebingen (Germany)
- 7. University College London, University College Hospital, Institute of Nuclear Medicine, London (United Kingdom)
- 8. Cambridge Computed Imaging Ltd, Cambridge (United Kingdom)
- 9. Mount Vernon Cancer Centre, Northwood (United Kingdom)
- 10. Gray Institute for Radiation, Oncology and Biology, Oxford (United Kingdom)
Description
Dynamic contrast-enhanced computed tomography (DCE-CT) assesses the vascular support of tumours through analysis of temporal changes in attenuation in blood vessels and tissues during a rapid series of images acquired with intravenous administration of iodinated contrast material. Commercial software for DCE-CT analysis allows pixel-by-pixel calculation of a range of validated physiological parameters and depiction as parametric maps. Clinical studies support the use of DCE-CT parameters as surrogates for physiological and molecular processes underlying tumour angiogenesis. DCE-CT has been used to provide biomarkers of drug action in early phase trials for the treatment of a range of cancers. DCE-CT can be appended to current imaging assessments of tumour response with the benefits of wide availability and low cost. This paper sets out guidelines for the use of DCE-CT in assessing tumour vascular support that were developed using a Delphi process. Recommendations encompass CT system requirements and quality assurance, radiation dosimetry, patient preparation, administration of contrast material, CT acquisition parameters, terminology and units, data processing and reporting. DCE-CT has reached technical maturity for use in therapeutic trials in oncology. The development of these consensus guidelines may promote broader application of DCE-CT for the evaluation of tumour vascularity. (orig.)
Availability note (English)
Available from: http://dx.doi.org/10.1007/s00330-012-2379-4Additional details
Identifiers
Publishing Information
- Journal Title
- European Radiology
- Journal Volume
- 22
- Journal Issue
- 7
- Journal Page Range
- p. 1430-1441
- ISSN
- 0938-7994
- CODEN
- EURAE3
INIS
- Country of Publication
- Germany
- Country of Input or Organization
- Germany
- INIS RN
- 43076220
- Subject category
- S62: RADIOLOGY AND NUCLEAR MEDICINE;
- Descriptors DEI
- ANGIOGENESIS; ANOXIA; BIOLOGICAL MARKERS; BLOOD FLOW; BLOOD VESSELS; CARCINOMAS; CLINICAL TRIALS; COMPUTERIZED TOMOGRAPHY; CONTRAST MEDIA; DYNAMIC FUNCTION STUDIES; INTRAVENOUS INJECTION; PHYSIOLOGY; RECOMMENDATIONS
- Descriptors DEC
- BODY; CARDIOVASCULAR SYSTEM; DIAGNOSTIC TECHNIQUES; DISEASES; INJECTION; INTAKE; NEOPLASMS; ORGANS; TESTING; TOMOGRAPHY